Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) has a beta value of 2.11 and has seen 7,790,272 shares traded in the last trading session. The company, currently valued at $94.37 Million, closed the last trade at $2.51 per share which meant it lost -$0.2 on the day or -7.72% during that session. The XERS stock price is -415.54% off its 52-week high price of $12.94 and 43.43% above the 52-week low of $1.42. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.12 Million shares traded. The 3-month trading volume is 919.19 Million shares.
The consensus among analysts is that Xeris Pharmaceuticals, Inc. (XERS) is a Buy stock at the moment, with a recommendation rating of 1.6. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 5 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.73.
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) trade information
Despite being -7.72% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jun 23 when the XERS stock price touched $5.69-5 or saw a rise of 55.89%. Year-to-date, Xeris Pharmaceuticals, Inc. shares have moved -64.4%, while the 5-day performance has seen it change -52.55%. Over the past 30 days, the shares of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) have changed -53.43%. Short interest in the company has seen 1.39 Million shares shorted with days to cover at 0.
Wall Street analysts have a consensus price target for the stock at $12.2, which means that the shares’ value could jump 386.06% from current levels. The projected low price target is $10 while the price target rests at a high of $15. In that case, then, we find that the current price level is +497.61% off the targeted high while a plunge would see the stock lose 298.41% from current levels.
Xeris Pharmaceuticals, Inc. (XERS) estimates and forecasts
Figures show that Xeris Pharmaceuticals, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -67.86% over the past 6 months, with this year growth rate of -36.38%, compared to 12.4% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 43% and 38.5% for the next quarter. Revenue growth from the last financial year stood is estimated to be +393.4%.
5 analysts offering their estimates for the company have set an average revenue estimate of $1.82 Million for the current quarter. 5 have an estimated revenue figure of $3.7 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $320Million and $323Million respectively for this quarter and the next, and analysts expect sales will grow by 468.7% for the current quarter and 1045.5% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +0% over the past 5 years. Earnings growth for 2020 is a modest -66.6% while over the next 5 years, the company’s earnings are expected to increase by 0%.
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS)’s Major holders
Insiders own 2.57% of the company shares, while shares held by institutions stand at 58.02% with a share float percentage of 59.55%. Investors are also buoyed by the number of investors in a company, with Xeris Pharmaceuticals, Inc. having a total of 86 institutions that hold shares in the company. The top two institutional holders are Deerfield Management Company, L.P. (Series C) with over 3.43 Million shares worth more than $6.69 Million. As of March 30, 2020, Deerfield Management Company, L.P. (Series C) held 9.13% of shares outstanding.
The other major institutional holder is Sessa Capital IM, L.P., with the holding of over 3.23 Million shares as of March 30, 2020. The firm’s total holdings are worth over $6.3 Million and represent 8.6% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Meridian Small Cap Growth Fund and Invesco Oppenheimer Global Opportunities Fund. As of March 30, 2020, the former fund manager holds about 3.4% shares in the company for having 1279123 shares of worth $2.49 Million while later fund manager owns 1Million shares of worth $6.37 Million as of January 30, 2020, which makes it owner of about 2.66% of company’s outstanding stock.